Expert Opinion on Therapeutic Patents最新文献_第6页

SGLT2 inhibitors for the treatment of diabetes: a patent review (2019-23). 用于治疗糖尿病的 SGLT2 抑制剂：专利回顾（2019-23）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-01 Epub Date: 2024-08-02 DOI: 10.1080/13543776.2024.2379929

Rahul Baghel, Nikita Chhikara, Pawan Kumar, Akhilesh Kumar Tamrakar

{"title":"SGLT2 inhibitors for the treatment of diabetes: a patent review (2019-23).","authors":"Rahul Baghel, Nikita Chhikara, Pawan Kumar, Akhilesh Kumar Tamrakar","doi":"10.1080/13543776.2024.2379929","DOIUrl":"10.1080/13543776.2024.2379929","url":null,"abstract":"Introduction: The sodium-glucose co-transporter 2 (SGLT2) inhibitors are FDA-approved class of drugs for diabetes management. They improve glycemic control by inducing glucosuria. Notwithstanding with potent anti-hyperglycemic activity, SGLT2 inhibitors are emerging as drugs with multifaceted therapeutic potential, evidenced for cardioprotective, renoprotective, antihypertensive, and neuroprotective activities. Continuous attempts are being accomplished through structural modification, development of new formulation, or combination with other drugs, to enhance the bioactivity spectrum of SGLT2 inhibitors for better management of diabetes and related complications.Areas covered: This review comprises a summary of patent applications, acquired using the Espacenet Patent Search database, concerning SGLT2 inhibitors from 2019 to 2023, with focus on improving therapeutic potentials in management of diabetes and metabolic complications.Expert opinion: SGLT2 inhibitors have provided an exciting treatment option for diabetes. Originally developed as anti-hyperglycemic agents, SGLT2 inhibitors exert pleiotropic metabolic responses and have emerged as promising antidiabetic agents with cardio-protective and reno-protective activities. Given their distinct therapeutic profile, SGLT2 inhibitors have revolutionized the management of diabetes and associated complications. Emerging evidences on their therapeutic potential against cancer, male reproductive dysfunctions, and neurodegenerative diseases indicate that further research in this field may unfold novel prospective on their plausible use in the management of other chronic conditions.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"807-823"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023). 作为抗癌剂的选择性 COX-2 抑制剂：专利综述（2018-2023 年）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-01 Epub Date: 2024-07-03 DOI: 10.1080/13543776.2024.2373771

Mohammad Mahboubi-Rabbani, Amir Hossein Abdolghaffari, Mahsa Ghesmati, Ali Amini, Afshin Zarghi

{"title":"Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023).","authors":"Mohammad Mahboubi-Rabbani, Amir Hossein Abdolghaffari, Mahsa Ghesmati, Ali Amini, Afshin Zarghi","doi":"10.1080/13543776.2024.2373771","DOIUrl":"10.1080/13543776.2024.2373771","url":null,"abstract":"Introduction: COX-2 is a crucial enzyme in the manufacture of prostaglandins. The enzyme's metabolites might have an important function as regulators of the inflammatory response and other medical conditions such as cancer. Selective COX-2 inhibitors are believed to enhance or reverse the response of cancer chemotherapeutics.Areas covered: This study addresses the chemical structures as well as the antitumor activity of new COX-2 inhibitors produced in the recent five years, aiming to provide an insight into the mechanism of COX-2 induced PGE2 powerful signal in cancer development.Expert opinion: The significance of selective COX-2 inhibitors as an efficient superfamily of compounds with anti-inflammatory, anti-Alzheimer's, anti-Parkinson's disease, and anticancer properties has piqued the passion of academics in the field of drug development. Long-term usage of selective COX-2 inhibitors, such as celecoxib has been proven in clinical trials to lower the incidence of several human malignancies. Furthermore, celecoxib has the potential to greatly increase the effectiveness of chemotherapy. Our extensive understanding of selective COX-2 inhibitor SAR may aid in the development of safer and more effective selective COX-2 inhibitors as cancer chemopreventive agents. This review focuses on the different structural classes of selective COX-2 inhibitors, with a particular emphasis on their SAR.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"733-757"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present). 多聚样激酶（PLK）抑制剂的进展：专利回顾（2018年至今）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-01 Epub Date: 2024-07-15 DOI: 10.1080/13543776.2024.2379924

Shirong Bian, Ru Zhang, Jianyu Nie, Mingxing Zhu, Zhouling Xie, Chenzhong Liao, Qin Wang

{"title":"Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present).","authors":"Shirong Bian, Ru Zhang, Jianyu Nie, Mingxing Zhu, Zhouling Xie, Chenzhong Liao, Qin Wang","doi":"10.1080/13543776.2024.2379924","DOIUrl":"10.1080/13543776.2024.2379924","url":null,"abstract":"Introduction: Polo-like kinases (PLKs) have five isoforms, all of which play crucial roles in cell cycle and cell proliferation, offering opportunities for drug design and treatment of cancers and other related diseases. Notably, PLK1 and PLK4 have been extensively investigated as cancer drug targets. One distinctive feature of PLKs is the presence of a unique polo-box domain (PBD), which regulates kinase activity and subcellular localization. This provides possibilities for specifically targeting PLKs.Area covered: This article provides an overview of the roles of PLKs in various cancers and related diseases, as well as the drug development involving PLKs, with a particular focus on PLK1 and PLK4. It summarizes the PLK1 and PLK4 inhibitors that have been disclosed in patents or literature (from 2018 - present), which were sourced from SciFinder and WIPO database.Expert opinion: After two decades of drug development on PLKs, several drugs progressed into clinical trials for the treatment of many cancers; however, none of them has been approved yet. Further elucidating the mechanisms of PLKs and identifying and developing highly selective ATP-competitive inhibitors, highly potent drug-like PBD inhibitors, degraders, etc. may provide new opportunities for cancer therapy and the treatment for several nononcologic diseases. PLKs inhibition-based combination therapies can be another helpful strategy.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"789-806"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020-present. 治疗癌症的小分子 CDK4/6 抑制剂专利回顾：2020 年至今。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-01 Epub Date: 2024-07-17 DOI: 10.1080/13543776.2024.2379926

Xiaoling Huang, Shidi Xu, Lei Duan, Shan Xu, Wufu Zhu

{"title":"A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020-present.","authors":"Xiaoling Huang, Shidi Xu, Lei Duan, Shan Xu, Wufu Zhu","doi":"10.1080/13543776.2024.2379926","DOIUrl":"10.1080/13543776.2024.2379926","url":null,"abstract":"Introduction: Cyclin-dependent protein kinase 4/6 (CDK4/6) is a class of serine/threonine protein kinases that plays a key role in the regulation of the cell cycle. CDK4/6 is highly expressed in cancers such as breast cancer, melanoma, and non-small cell lung cancer (NSCLC). Currently, a variety of CDK4/6 inhibitors have been developed, aiming to develop effective inhibitors to solve CDK4/6 resistance and toxicity.Areas covered: This article searches patents through Espacenet and reviews the development of widely studied CDK inhibitors and FDA-approved CDK4/6 inhibitors, as well as the latest progress of patented inhibitors with good inhibitory activity against CDK4/6 from 2020 to now.Expert opinion: CDK4/6 is highly expressed in many tumors and has become an important anti-tumor target. Among the patents from 2020 to the present, many inhibitors have good kinase inhibitory effects on CDK4/6 and also show great development potential in anti-tumor. However, there is still an urgent need to develop novel CDK4/6 inhibitors that address challenges such as drug resistance, toxicity, and selectivity.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"825-842"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to date. 治疗帕金森病的富亮氨酸重复激酶 2 (LRRK2) 抑制剂：迄今为止的专利文献综述。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-01 Epub Date: 2024-07-19 DOI: 10.1080/13543776.2024.2378076

Margaux Morez, Antonio Jesús Lara Ordóñez, Patricia Melnyk, Maxime Liberelle, Nicolas Lebègue, Jean-Marc Taymans

引用次数: 0

The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present). 磷酸二酯酶 9（PDE9）抑制剂的治疗潜力：专利综述（2018 年至今）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-01 Epub Date: 2024-07-09 DOI: 10.1080/13543776.2024.2376632

Chen Zhang, Zhao-Hang Xue, Wei-Hao Luo, Mei-Yan Jiang, Yinuo Wu

{"title":"The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present).","authors":"Chen Zhang, Zhao-Hang Xue, Wei-Hao Luo, Mei-Yan Jiang, Yinuo Wu","doi":"10.1080/13543776.2024.2376632","DOIUrl":"10.1080/13543776.2024.2376632","url":null,"abstract":"Introduction: Phosphodiesterase 9 (PDE9) has been demonstrated as a potential target for neurological disorders and cardiovascular diseases, such as Alzheimer's disease and heart failure. For the last few years, a series of PDE9 inhibitors with structural diversities have been developed and patented by researchers and pharmaceutical companies, providing insights into first-in-class therapies of PDE9 drug candidates.Area covered: This review provides an overview of PDE9 inhibitors in patents from 2018 to the present.Expert opinion: Only a few of the current PDE9 inhibitors are highly selective over other PDEs, which limits their application in pharmacological and clinical research. The design and development of highly selective PDE9 inhibitors remain the top priority in future research. The advantages of targeting PDE9 rather than other PDEs in treating neurodegenerative diseases need to be explained thoroughly. Besides, application of PDE9 inhibitor-based combination therapies sheds light on treating diabetes and refractory heart diseases. Finally, PDE9 inhibitors should be further explored in clinical indications beyond neurological disorders and cardiovascular diseases.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"759-772"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic potential of boswellic acids: an update patent review (2016-2023). 乳香酸的治疗潜力：最新专利综述（2016-2023 年）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-08-01 Epub Date: 2024-07-05 DOI: 10.1080/13543776.2024.2369626

Hidayat Hussain, Daijie Wang, Hesham R El-Seedi, Luay Rashan, Ishtiaq Ahmed, Muzaffar Abbas, Nilufar Z Mamadalieva, Haider N Sultani, Muhammad Iftikhar Hussain, Syed Tasadaque A Shah

{"title":"Therapeutic potential of boswellic acids: an update patent review (2016-2023).","authors":"Hidayat Hussain, Daijie Wang, Hesham R El-Seedi, Luay Rashan, Ishtiaq Ahmed, Muzaffar Abbas, Nilufar Z Mamadalieva, Haider N Sultani, Muhammad Iftikhar Hussain, Syed Tasadaque A Shah","doi":"10.1080/13543776.2024.2369626","DOIUrl":"10.1080/13543776.2024.2369626","url":null,"abstract":"Introduction: Boswellic acids (BAs) are a group of pentacyclic triterpenoids of the ursane and oleanane type. They have shown very interesting biological properties that have led to the development of a number of synthesis protocols. Both natural BAs and their synthetic derivatives may be useful in the treatment of a variety of cancers, viral infections and inflammatory diseases.Areas covered: This review covers patents relating to the therapeutic activities of natural BAs and their synthetic derivatives. The latest patented studies of boswellic acids (are summarized by using the keywords 'boswellic acid,' in SciFinder, PubMed, and Google Patents and databases in the year from 2016 to 2023.Expert opinion: Boswellic acids have shown potent antiviral, anticancer and anti-inflammatory potential. Few BAs analogues have been prepared by modification at the C24-CO2H functional groups. In particular, the C-24 amide and amino analogues have shown enhanced anticancer effects compared to the parent AKBA. In addition, BAs have the ability to form conjugates with other antiviral, anti-inflammatory and anticancer drugs that synergistically enhance their biological efficacy. In addition, this conjugation strategy will increase the solubility and bioavailability of BAs, which is one of the most important issues in the development of BAs.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"723-732"},"PeriodicalIF":5.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in the development of P2Y₁₄R inhibitors: a patent and literature review (2018-present). P2Y14R 抑制剂开发的最新进展：专利和文献综述（2018 年至今）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-08-01 Epub Date: 2024-06-19 DOI: 10.1080/13543776.2024.2369634

Kai Wang, Fen Zhong, Zhou-Dong Zhang, Huan-Qiu Li, Sheng Tian

{"title":"Recent advances in the development of P2Y14R inhibitors: a patent and literature review (2018-present).","authors":"Kai Wang, Fen Zhong, Zhou-Dong Zhang, Huan-Qiu Li, Sheng Tian","doi":"10.1080/13543776.2024.2369634","DOIUrl":"10.1080/13543776.2024.2369634","url":null,"abstract":"Introduction: The P2Y14 receptor (P2Y14R), a member of the G protein-coupled receptor family, is activated by extracellular nucleotides. Due to its involvement in inflammatory, immunological and other associated processes, P2Y14R has emerged as a promising therapeutic target. Despite lacking a determined three-dimensional crystal structure, the homology modeling technique based on closely related P2Y receptors' crystallography has been extensively utilized for developing active compounds targeting P2Y14R. Recent discoveries have unveiled numerous highly effective and subtype-specific P2Y14R inhibitors. This study presents an overview of the latest advancements in P2Y14R inhibitors.Areas covered: This review presents an overview of the advancements in P2Y14R inhibitor research over the past five years, encompassing new patents, journal articles, and highlighting the therapeutic prospects inherent in these compounds.Expert opinion: The recent revelation of the vast potential of P2Y14R inhibitors has led to the development of novel compounds that exhibit promising capabilities for the treatment of sterile inflammation of the kidney, potentially diabetes, and asthma. Despite being a relatively nascent class of compounds, certain members have already exhibited their capacity to surmount specific challenges posed by conventional P2Y14R inhibitors. Targeting P2Y14R through small molecules may present a promising therapeutic strategy for effectively managing diverse inflammatory diseases.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"611-625"},"PeriodicalIF":5.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patent review of cannabinoid receptor type 2 (CB₂R) modulators (2016-present). 大麻素受体 2 型（CB2R）调节剂专利回顾（2016 年至今）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-08-01 Epub Date: 2024-07-02 DOI: 10.1080/13543776.2024.2368745

Miroslav Kosar, Leonard Mach, Erick M Carreira, Marc Nazaré, Pal Pacher, Uwe Grether

{"title":"Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).","authors":"Miroslav Kosar, Leonard Mach, Erick M Carreira, Marc Nazaré, Pal Pacher, Uwe Grether","doi":"10.1080/13543776.2024.2368745","DOIUrl":"10.1080/13543776.2024.2368745","url":null,"abstract":"Introduction: Cannabinoid receptor type 2 (CB2R), predominantly expressed in immune tissues, is believed to play a crucial role within the body's protective mechanisms. Its modulation holds immense therapeutic promise for addressing a wide spectrum of dysbiotic conditions, including cardiovascular, gastrointestinal, liver, kidney, neurodegenerative, psychiatric, bone, skin, and autoimmune diseases, as well as lung disorders, cancer, and pain management.Areas covered: This review is an account of patents from 2016 up to 2023 which describes novel CB2R ligands, therapeutic applications, synthesis, as well as formulations of CB2R modulators.Expert opinion: The patents cover a vast, structurally diverse chemical space. The focus of CB2R ligand development has shifted from unselective dual-cannabinoid receptor type 1 (CB1R) and 2 agonists toward agonists with high selectivity over CB1R, particularly for indications associated with inflammation and tissue injury. Currently, there are at least eight CB2R agonists and one antagonist in active clinical development. A better understanding of the endocannabinoid system (ECS) and in particular of CB2R pharmacology is required to unlock the receptor's full therapeutic potential.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"665-700"},"PeriodicalIF":5.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhibition of GTPase KRAS^G12D: a review of patent literature. 抑制 GTPase KRASG12D：专利文献综述。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-08-01 Epub Date: 2024-06-26 DOI: 10.1080/13543776.2024.2369630

Yuhang Li, Le Yang, Xiaoran Li, Xiaojin Zhang

{"title":"Inhibition of GTPase KRASG12D: a review of patent literature.","authors":"Yuhang Li, Le Yang, Xiaoran Li, Xiaojin Zhang","doi":"10.1080/13543776.2024.2369630","DOIUrl":"10.1080/13543776.2024.2369630","url":null,"abstract":"Introduction: KRAS is a critical oncogenic protein intricately involved in tumor progression, and the difficulty in targeting KRAS has led it to be classified as an 'undruggable target.' Among the various KRAS mutations, KRASG12D is highly prevalent and represents a promising therapeutic target, yet there are currently no approved inhibitors for it.Area covered: This review summarizes numerous patents and literature featuring inhibitors or degraders of KRASG12D through searching relevant information in PubMed, SciFinder and Web of Science databases from 2021 to February 2024, providing an overview of the research progress on inhibiting KRASG12D in terms of design strategies, chemical structures, biological activities, and clinical advancements.Expert opinion: Since the approval of AMG510 (Sotorasib), there has been an increasing focus on the inhibition of KRASG12D, leading to numerous reports of related inhibitors and degraders. Among them, MRTX1133, as the first KRASG12D inhibitor to enter clinical trials, has demonstrated excellent tumor suppression in various KRASG12D-bearing human tumor xenograft models. It is important to note, however, that understanding the mechanisms of acquired resistance caused by KRAS inhibition and developing additional combination therapies is crucial. Moreover, seeking covalent inhibition of KRASG12D also holds significant potential.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"701-721"},"PeriodicalIF":5.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0